These included 4/7 (57%) CD56−/lo CLPD-NK patients, 7/16 (44%) Tγδ+-LGLL, 12/33 (36%) TCD8+-LGLL, and 2/7 (29%) CD56+ CLPD-NK, in addition to the single TCRαβ+CD4+CD8+ (Tαβ+DP—double-positive) case analyzed, and 1/2 Tαβ+DN-LGLL patients studied (Table 1A). The gene discussed is NCAM1; the disease is T-cell large granular lymphocyte leukemia.